Journals should select drug advertisements more carefully

BMJ 2003; 326 doi: http://dx.doi.org/10.1136/bmj.326.7400.1211 (Published 29 May 2003)
Cite this as: BMJ 2003;326:1211.1

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. James J Oliver, specialist registrar in clinical pharmacology (james.oliver@ed.ac.uk),
  2. Simon R Maxwell, senior lecturer in clinical pharmacology
  1. Clinical Pharmacology Unit, Western General Hospital, Edinburgh EH4 2XU

    EDITOR—Until the ALLHAT study (antihypertensive and lipid lowering treatment to prevent heart attack trial) was published,1 there was little, if any, evidence of the clinical benefit of amlodipine in treating hypertension. Nevertheless, as testimony to the marketing success of Pfizer, amlodipine has become the world's biggest selling antihypertensive drug.

    Pfizer is obviously keen to publicise the …

    Get access to this article and all of bmj.com for the next 14 days

    Sign up for a 14 day free trial today

    Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL